IFN-α and Bortezomib Overcome Bcl-2 and Mcl-1 Overexpression in Melanoma Cells by Stimulating the Extrinsic Pathway of Apoptosis

作者: Gregory B. Lesinski , Ene T. Raig , Kristan Guenterberg , Lloyd Brown , Michael R. Go

DOI: 10.1158/0008-5472.CAN-08-0426

关键词:

摘要: We hypothesized that IFN-α would enhance the apoptotic activity of bortezomib on melanoma cells. Combined treatment with and induced synergistic apoptosis in other solid tumor cell lines. Apoptosis was associated processing procaspase-3, procaspase-7, procaspase-8, procaspase-9 cleavage Bid poly(ADP-ribose) polymerase. Bortezomib plus effective at inducing cells overexpressed Bcl-2 or Mcl-1, suggesting this combination can overcome mitochondrial pathways survival resistance to apoptosis. The proapoptotic effects were abrogated by a caspase-8 inhibitor, led increased association Fas FADD before onset death, significantly reduced transfected dominant-negative construct small interfering RNA targeting Fas. These data suggest act through extrinsic pathway via FADD-induced activation initiate death. Finally, displayed statistically significant antitumor compared either agent alone both B16 murine model athymic mice bearing human A375 xenografts. support future clinical development for malignant melanoma. [Cancer Res 2008;68(20):8351–60]

参考文章(49)
Ronald M. Bukowski, Cytokine therapy for metastatic renal cell carcinoma. Seminars in Urologic Oncology. ,vol. 19, pp. 148- 154 ,(2001)
Mamta Chawla-Sarkar, Daniel J Lindner, Y-F Liu, BR Williams, Ganes C Sen, Robert H Silverman, Ernest C Borden, Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis. Apoptosis. ,vol. 8, pp. 237- 249 ,(2003) , 10.1023/A:1023668705040
Teru Hideshima, Dharminder Chauhan, Paul Richardson, Constantine Mitsiades, Nicholas Mitsiades, Toshiaki Hayashi, Nikhil Munshi, Lenny Dang, Alfredo Castro, Vito Palombella, Julian Adams, Kenneth C. Anderson, NF-κB as a Therapeutic Target in Multiple Myeloma * Journal of Biological Chemistry. ,vol. 277, pp. 16639- 16647 ,(2002) , 10.1074/JBC.M200360200
David J. McConkey, Steffan T. Nawrocki, Ryan Takamori, Bridget Sweeney-Gotsch, The proteasome inhibitor bortezomib enhances the activity of docetaxel in orthotopic human pancreatic tumor zenografts Molecular Cancer Therapeutics. ,vol. 3, pp. 59- 70 ,(2004)
Leigh Coultas, Andrew S. Kraft, Andrew S. Kraft, Thomas Johnson, Thomas Johnson, Jerry Adams, Hamsa Puthalalath, Malti Nikrad, The proteasome inhibitor bortezomib sensitizes cells to killing by death receptor ligand TRAIL via BH3-only proteins Bik and Bim Molecular Cancer Therapeutics. ,vol. 4, pp. 443- 449 ,(2005) , 10.1158/1535-7163.MCT-04-0260
Tahira Khan, Jimmy K. Stauffer, Rebecca Williams, Julie A. Hixon, Rosalba Salcedo, Erin Lincoln, Timothy C. Back, Douglas Powell, Stephen Lockett, Alma C. Arnold, Thomas J. Sayers, Jon M. Wigginton, Proteasome Inhibition to Maximize the Apoptotic Potential of Cytokine Therapy for Murine Neuroblastoma Tumors Journal of Immunology. ,vol. 176, pp. 6302- 6312 ,(2006) , 10.4049/JIMMUNOL.176.10.6302
Natalya V. Guseva, Agshin F. Taghiyev, Oskar W. Rokhlin, Michael B. Cohen, Contribution of death receptor and mitochondrial pathways to Fas-mediated apoptosis in the prostatic carcinoma cell line PC3. The Prostate. ,vol. 51, pp. 231- 240 ,(2002) , 10.1002/PROS.10095
James F. Curtin, Thomas G. Cotter, Live and let die: regulatory mechanisms in Fas-mediated apoptosis Cellular Signalling. ,vol. 15, pp. 983- 992 ,(2003) , 10.1016/S0898-6568(03)00093-7
Rong-Guang Shao, Chun-Xia Cao, Wilberto Nieves-Neira, Marie-Thérèse Dimanche-Boitrel, Eric Solary, Yves Pommier, Activation of the Fas pathway independently of Fas ligand during apoptosis induced by camptothecin in p53 mutant human colon carcinoma cells Oncogene. ,vol. 20, pp. 1852- 1859 ,(2001) , 10.1038/SJ.ONC.1204264
J D Kelly, J Dai, P Eschwege, J S Goldberg, B P Duggan, K E Williamson, N H Bander, D M Nanus, Downregulation of Bcl-2 sensitises interferon-resistant renal cancer cells to Fas British Journal of Cancer. ,vol. 91, pp. 164- 170 ,(2004) , 10.1038/SJ.BJC.6601895